Health TrialsbyHealthPanel

The GBA Multimodal Study in Parkinson's Disease

ConditionsParkinson DiseaseGBA Gene MutationGaucher Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorPacific Parkinson's Research Centre

About this trial

This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

heterozygous for a pathogenic GBA mutation (e.g., p.L444P, p.N370S) or polymorphism;

age 18 to 80 years.

Disqualifiers

co-occurrence of other neurological disorders;

implants that contraindicate the MRI scanning (e.g. cardiac pacemaker, ferromagnetic implants or devices);

severe claustrophobia;

intolerance to antiparkinsonian drug withdrawal (for GBA-PD subjects);

Trial population

People with a known pathogenic GBA gene mutation with or without PD.

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • PET scan

    Diagnostic test

    3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.

  • neuroQWERTY

    Diagnostic test

    Analysis of free-text typing in a computer and/or a touch-screen device.

Treatment groups

25 Participants
are divided into 2 treatment groups
Group A: GBA-PD2 interventions
Group B: Asymptomatic GBA2 interventions

Trial outcomes

Primary outcomes

1

Acetylcholinesterase activity

11C-PMP PET

Time frame
baseline
2

Tau protein deposition

11C-PBB3 PET

Time frame
baseline
3

Dopaminergic denervation

11C-DTBZ PET

Time frame
baseline
4

neuroQWERTY index

Typing analysis

Time frame
baseline

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Pacific Parkinson's Research Centre

Lead sponsor

University of British Columbia

Collaborator

University of Washington

Collaborator

Oregon Health and Science University

Collaborator

Simon Fraser University

Collaborator

Michael J. Fox Foundation for Parkinson's Research

Collaborator

Silverstein Foundation

Collaborator

Weston Brain Institute

Collaborator

Source ClinicalTrials.gov
Apply now